Literature DB >> 28133306

[Effectiveness of Irinotecan, S-1, and Bevacizumab for Rectal Cancer with Lung and Skin Metastases after Adjuvant Chemotherapy].

Kiyotaka Hagihara1, Masataka Ikeda, Sakae Maeda, Mamoru Uemura, Kazuyoshi Yamamoto, Masakazu Miyake, Naoki Hama, Kazuhiro Nishikawa, Atsushi Miyamoto, Hideyasu Omiya, Michihiko Miyazaki, Motohiro Hirao, Koji Takami, Shoji Nakamori, Mitsugu Sekimoto.   

Abstract

A 50-year-old woman with a chief complaint of bloody stools was diagnosed with rectal cancer via colonoscopy. Laparoscopic rectal anterior resection with D3 lymph node dissection was performed in June 2014. The pathological diagnosis was pStage III a(Ra, pT3, N1)cancer, and the patient received 8 courses of XELOX as postoperative adjuvant chemotherapy. During follow-up at 12 months after surgery, chest computed tomography revealed a mass in the left lingular segment measuring 25mm in diameter and multiple small nodules in both the lungs, indicating lung metastases. We found several subcutaneous nodules with a maximum diameter of 10mm in her abdomen and the back of head. We removed 3 subcutaneous nodules for the purpose of diagnosis and treatment in June of 2015. The pathological findings were consistent with cutaneous metastases of rectal cancer. The patient received a 1 course of IRIS and 5 courses of IRIS plus bevacizumab. Subsequently, the lung metastases disappeared and no new skin lesions were detected. We suggest that this case could be a good reference in determining the appropriate treatment for rectal cancer having lung or cutaneous metastases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28133306

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.

Authors:  Yuefeng Hu; Dong Liu; Peilin Cui; Wen Zhang; Hao Chen; Chunmei Piao; Yongcheng Lu; Xuesong Liu; Yue Wang; Jingwei Liu; Xu Lu
Journal:  Invest New Drugs       Date:  2021-08-13       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.